Department of Urology, University of California, San Francisco, CA, USA.
Cancer. 2010 Nov 15;116(22):5226-34. doi: 10.1002/cncr.25456.
Because no adequate randomized trials have compared active treatment modalities for localized prostate cancer, the authors analyzed risk-adjusted, cancer-specific mortality outcomes among men who underwent radical prostatectomy, men who received external-beam radiation therapy, and men who received primary androgen-deprivation therapy.
The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry comprises men from 40 urologic practice sites who are followed prospectively under uniform protocols, regardless of treatment. In the current study, 7538 men with localized disease were analyzed. Prostate cancer risk was assessed using the Kattan preoperative nomogram and the Cancer of the Prostate Risk Assessment (CAPRA) score, both well validated instruments that are calculated from clinical data at the time of diagnosis. A parametric survival model was constructed to compare outcomes across treatments adjusting for risk and age.
In total, 266 men died of prostate cancer during follow-up. Adjusting for age and risk, the hazard ratio for cancer-specific mortality relative to prostatectomy was 2.21 (95% confidence interval [CI], 1.50-3.24) for radiation therapy and 3.22 (95% CI, 2.16-4.81) for androgen deprivation. Absolute differences between prostatectomy and radiation therapy were small for men at low risk but increased substantially for men at intermediate and high risk. These results were robust to a variety of different analytic techniques, including competing risks regression analysis, adjustment by CAPRA score rather than Kattan score, and examination of overall survival as the endpoint.
Prostatectomy for localized prostate cancer was associated with a significant and substantial reduction in mortality relative to radiation therapy and androgen-deprivation monotherapy. Although this was not a randomized study, given the multiple adjustments and sensitivity analyses, it is unlikely that unmeasured confounding would account for the large observed differences in survival.
由于没有充分的随机试验比较局限性前列腺癌的积极治疗方式,作者分析了接受根治性前列腺切除术、外照射放疗和雄激素剥夺治疗的患者的风险调整后癌症特异性死亡率结果。
癌症前列腺策略性泌尿科研究努力(CaPSURE)登记处包括来自 40 个泌尿科诊所的前瞻性随访男性患者,无论治疗方式如何,均遵循统一的方案。在本研究中,分析了 7538 名局限性疾病患者。使用 Kattan 术前列腺癌风险预测模型和前列腺癌风险评估(CAPRA)评分评估前列腺癌风险,这两个模型都是在诊断时根据临床数据计算的,均经过充分验证。构建了一个参数生存模型,通过调整风险和年龄,比较了不同治疗方法的结果。
在随访期间,共有 266 例患者死于前列腺癌。调整年龄和风险后,与前列腺切除术相比,放疗的癌症特异性死亡率的风险比为 2.21(95%置信区间[CI],1.50-3.24),雄激素剥夺治疗的风险比为 3.22(95%CI,2.16-4.81)。对于低危患者,前列腺切除术与放疗之间的绝对差异较小,但对于中危和高危患者,差异显著增加。这些结果对于各种不同的分析技术是稳健的,包括竞争风险回归分析、使用 CAPRA 评分而不是 Kattan 评分进行调整,以及将总生存作为终点进行检查。
与放疗和雄激素剥夺单药治疗相比,局限性前列腺癌行前列腺切除术与死亡率显著降低相关。虽然这不是一项随机研究,但鉴于多种调整和敏感性分析,不太可能存在未测量的混杂因素会导致观察到的生存差异如此之大。